CPS Technologies (NasdaqCM:CPSH) Q4 2025 Earnings call March 03, 2026 09:00 AM ET Company ParticipantsBrian Mackey - President and CEOChris Witty - Investor Relations AdvisorChuck Griffith - CFOJoe Schicker - ShareholderSteven Fossey - ShareholderConference Call ParticipantsChip Moore - Managing Director and Senior Research AnalystOperatorGood morning, everyone. Welcome to CPS Technologies' fourth quarter 2025 earnings call. At this time, all participants have been placed on a listen-only mode, and the floo ...

Honeywell International FY Conference Summary Company Overview - **Company**: Honeywell International (NasdaqGS: HON) - **Date of Conference**: February 17, 2026 Key Industry Insights Aerospace Demand - Aerospace demand remains very strong, with expectations for another robust year in 2026 [2][11] - The company has seen a consistent double-digit growth in aerospace volume for 15 consecutive quarters [70] Industrial Automation - North America is performing exceptionally well in industrial automation, while Europe and China show flat to slightly negative trends [2][7] - The industrial automation business is increasingly focused on sensing and measurement, which is linked to local economic conditions [6][7] Process Markets - The process markets are expected to experience flat growth due to overcapacity and cautious customer investment [3][9] - LNG and refining sectors show high demand, but excess capacity in petrochemicals is hindering investment [9] Building Automation - Demand for building automation remains strong, with a focus on high-growth end markets such as data centers, hospitality, hospitals, and clean tech [45][46][47] Financial Performance and Projections Revenue Growth - Honeywell projects a revenue growth of 3%-6% for 2026, with expectations for stronger performance in the second half of the year due to a higher backlog [14][15] - The backlog in process automation and technology is up double-digit, indicating potential revenue uplift in the latter half of the year [11] Cost and Pricing Environment - The industrial economy is experiencing high inflation, with price increases of 3%-4% expected to continue [17][18] - Honeywell is adapting its pricing strategy to manage inflation, focusing on productivity and new product development to maintain margins [21][22] R&D Investment - Honeywell's R&D spending is at or above the median of the industry, with a focus on spending wisely to ensure effective outcomes [25][26] Strategic Focus Areas Mergers and Acquisitions - Near-term focus is on debt retirement to maintain an investment-grade rating, with potential for bolt-on acquisitions in automation post-spin [39][40] - The company aims to create a new category in industrial automation, leveraging its existing $4 billion sensing and measurement business [41] Margin Expansion - Honeywell aims for high single-digit earnings growth and a margin expansion of 30-50 basis points annually [34][35] - Factors contributing to margin improvement include normalization of OE mix, resolution of integration costs from past acquisitions, and reduced supply chain costs [52][54] Challenges and Risks - The company faces challenges in passing through costs due to long-term contracts in the aerospace sector, with significant impacts expected from contract renewals in 2027 [56][58] - Stranded costs from the upcoming spin-off are anticipated to be in line with market standards, with a focus on managing these effectively [59][60] Conclusion Honeywell International is positioned for growth in 2026, driven by strong demand in aerospace and building automation, while facing challenges in industrial automation and process markets. The company is strategically focused on managing costs, enhancing productivity, and pursuing targeted acquisitions to strengthen its market position.

Financial Data and Key Metrics Changes - For Q2 2026, net sales were $118.2 million, reflecting a 9% increase from $108.5 million in the prior year quarter, marking the ninth consecutive quarter of year-over-year sales growth [12] - GAAP operating income for the quarter was $9.0 million, or 7.6% of sales, compared to $11.7 million in the prior year quarter, which included a $5 million gain from the sale of a manufacturing facility [12][13] - The current quarter's operating income increased by 35% compared to adjusted operating income of $6.7 million or 6.1% of sales in the prior year quarter [13] Business Line Data and Key Metrics Changes - The increase in sales was primarily driven by higher unit volume in sourced soft seating products and pricing from tariff surcharges, partially offset by lower unit volume in made-to-order soft seating products and Homestyles branded ready-to-assemble products [12] - Sales order backlog at the end of the period was $82.4 million, which includes estimated tariff surcharges [12] Market Data and Key Metrics Changes - Industry demand remains uneven, with consumer behavior showing variability, influenced by economic uncertainty and inflation concerns [8] - Feedback from retail partners indicates that consumer engagement fluctuates, impacting overall industry demand [8] Company Strategy and Development Direction - The company is focusing on long-term value creation while navigating a dynamic external environment, emphasizing agility and discipline [4] - Investments in consumer insights, product development, and innovation are aimed at improving the effectiveness of new product launches [5] - The company is actively evaluating broader cost reduction opportunities and alternative supply chain options to strengthen its long-term position [10] Management's Comments on Operating Environment and Future Outlook - The management acknowledges that the U.S. economy shows resilience, but housing activity and discretionary spending remain inconsistent, weighing on overall industry demand [8] - Tariff policies are evolving, creating uncertainty for the furniture industry, and the company is prepared to adapt to these changes [9] - The management expresses confidence in the company's ability to manage near-term volatility while continuing to invest in growth platforms [10] Other Important Information - The company ended the quarter with a cash balance of $36.8 million and working capital of $126 million, with no bank debt [14] - The increase in working capital was driven by higher cost inventory due to tariffs and an intentional increase in safety stock of top-selling products [15] Q&A Session Summary Question: Can you talk about unit volumes and pricing as far as how that impacted the quarter? - The tariff revenue in the quarter was approximately $9.5 million, with unit volumes relatively flat compared to the prior quarter, although some categories saw gains while others experienced declines [19][20] Question: What portion of your sales is now coming from new products? - Over the last 6-8 quarters, 30%-40% of overall sales have been derived from new products, which is a substantial driver for gaining market share [22] Question: Are there additional retailers that you think you may be underpenetrated in? - The company has aligned its business model around 20 large independent retailers and sees potential for significant growth with both existing and emerging relationships [25][26] Question: How do you expect to offset tariff impacts going forward? - The company has been able to mitigate tariff impacts through pricing actions and cost savings initiatives, but expects some margin dilution in the second half of the fiscal year due to higher cost inventory burdened with tariffs [29][31] Question: Was there anything unusual regarding the tax rate this quarter? - There was a slight impact related to foreign taxes, but the tax rate going forward is expected to align more closely with the full-year tax rate [32]

Financial Data and Key Metrics Changes - Total revenue increased approximately 16.6% year-on-year to $221.3 million, reflecting organic growth of 6.4%, a 9.4% benefit from acquisitions, and a 0.8% benefit from foreign currency [11] - Adjusted operating margin increased 30 basis points year-on-year to 19% [11] - Adjusted earnings per share increased 8.9% year-on-year to $2.08 [11] - Free cash flow for the second quarter was $13 million, compared to $2.2 million a year ago [12] - Net cash provided by operating activities was $20.7 million in the second quarter, compared to $9.1 million a year ago [11] Business Line Data and Key Metrics Changes - Electronics segment revenue increased 20.6% year-on-year to a record $115.7 million, driven by organic growth of 11.1% and acquisition benefits of 9.1% [12] - Engineering Technologies revenue increased 35.3% to $30.6 million, driven by a 33.4% benefit from the recent McStarlite acquisition [15] - Scientific revenue increased 5.5% to $19.5 million, due to an acquisition benefit of 8.1%, partially offset by an organic decline of 2.6% [16] - Engraving revenue increased 13.6% to $35.7 million, driven by organic growth of 10.3% [17] - Specialty Solutions segment revenue decreased 7.2% year-on-year to $19.8 million [17] Market Data and Key Metrics Changes - Sales into fast growth markets were approximately $61 million, accounting for 28% of total sales [6] - Sales from fast growth markets are expected to grow over 45% year-on-year and exceed $270 million [9] - The company expects mid- to high single-digit organic growth in the fiscal third quarter [4] Company Strategy and Development Direction - The company is focused on aligning organic and inorganic growth investments around secular end markets and new products [20] - The strategy includes increasing R&D spending from 1% of sales to 3% to support new product development [6] - The company aims to expand its presence in fast growth markets such as grid, commercialization of space, and defense [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid- to high single-digit organic growth in the fiscal third quarter and reiterated the fiscal year 2026 sales outlook [4][8] - The company is well-positioned to deliver strong results due to the momentum from new product sales and fast growth markets [20] - Management noted that clarity in trade agreements, such as the recent India-EU trade deal, is beneficial for long-term planning and investment [35] Other Important Information - The company paid down approximately $10 million of debt, reducing the net leverage ratio to 2.3 [8] - The company declared a quarterly cash dividend of $0.34 per share, an increase of approximately 6.3% year-on-year [19] - The company expects capital expenditures between $33 million and $38 million for fiscal 2026 [19] Q&A Session Summary Question: Can you walk us through the purchase accounting side related to the Amran and Narayan acquisition? - Management explained the technical aspects of the acquisition and the need for government approval for the remaining 10% of Narayan, which has not been obtained [25][27][29] Question: How would you characterize the competitive environment for the Grid business? - Management described the market as one of customer intimacy, with OEMs increasingly outsourcing low to medium voltage transformers, and highlighted the company's strong relationships with major OEMs [30][32] Question: Can you provide insights on the sales and order growth for the Grid business versus the legacy business? - Management indicated that the Grid business has a book-to-bill ratio of about 1.2, while the core business is around 1.03 to 1.04, with strong demand in the Grid sector [42][45] Question: What is the status of capacity expansion projects in Houston, Mexico, and Croatia? - Management confirmed that capacity has increased by about 50% since the acquisition and that new sites are ramping up, with plans to more than double capacity in the next 3-5 years [62][63] Question: What are the expectations for fast growth sales and the impact of the Amran acquisition? - Management expects fast growth sales to exceed $270 million, with over half attributed to the Grid business, and noted that the Amran acquisition has been beneficial for overall growth [84][86]

Core Viewpoint - The company has developed a new type of tantalum capacitor product with innovative processes, aimed at high-end consumer electronics, AI data centers, enterprise-level ESSD, automotive electronics, and industrial control sectors [1] Group 1: Product Development and Innovation - The company has invested in research and development of tantalum capacitor products for many years, leading to significant advancements in materials, processes, and manufacturing [1] - The new tantalum capacitor products are designed to meet the stringent quality requirements of global high-end electronic manufacturers [1] Group 2: Market Position and Strategy - The company aims to become a leading supplier in the tantalum capacitor industry in the long term [1] - The company has established a solid foundation for steady growth by continuously innovating and expanding its market application areas [1] Group 3: Customer Engagement and Recognition - The company has successfully supplied various tantalum capacitor products to its clients, achieving high customer recognition and ongoing market progress [1]

Core Viewpoint - The company emphasizes its commitment to fulfilling information disclosure obligations and focuses on strategic initiatives to enhance product development, scale expansion, and market collaboration [1] Group 1: Company Strategy - The company is accelerating new product development as part of its strategic focus [1] - It aims to expand product scale to strengthen its market position [1] - The company is enhancing domestic and international market collaboration to support growth [1] Group 2: Operational Improvement - The company is working to solidify its development foundation and improve operational efficiency [1] - Efforts are being made to increase capital returns for stakeholders [1]

Core Viewpoint - The stock price of Mindray Medical (300760.SZ) has fallen below 200 yuan, significantly down from its historical high of nearly 500 yuan, indicating a substantial decline in market value. The actual controller, Li Xiting, has recently increased his stake by approximately 200 million yuan, but this is minor compared to the over 10 billion yuan he has cashed out through significant reductions in shareholding over the past three years. Analysts suggest that while the company faces ongoing challenges in the domestic medical supply market and overseas tariff risks, there may be potential for a turnaround in both stock price and fundamentals after four years of adjustment [3][4][5][9]. Group 1: Shareholding Changes - From November 27 to December 12, Li Xiting used 200 million yuan to acquire 1.005 million shares of Mindray Medical, representing 0.08% of the total share capital. This buyback was completed ahead of the originally planned six-month period [4]. - Following the buyback, Li Xiting and his associates hold a total of 625 million shares, accounting for 51.55% of the company [4]. - Over the past three years, Li Xiting's platforms have significantly reduced their holdings, cashing out approximately 25 billion yuan in a single quarter and over 10 billion yuan in total [5]. Group 2: Financial Performance - In the first three quarters of the year, Mindray Medical reported revenue of 25.834 billion yuan, a year-on-year decrease of 12.38%, and a net profit of 7.57 billion yuan, down 29%. However, the third quarter showed signs of recovery with a revenue of 9.091 billion yuan, a year-on-year increase of 1.53% [8]. - Analysts predict that with the recovery of domestic bidding and accelerated overseas expansion, the company's revenue and profit may gradually stabilize. However, the sales net profit margin has decreased to 30.2%, down 6.1 percentage points year-on-year [8]. Group 3: Market Outlook and Challenges - Mindray Medical has submitted an application for H-share issuance and main board listing, indicating a strategic move to enhance its market position [9]. - Despite the recent increase in shareholding by Li Xiting, analysts express concerns that this may signal a reduction in future support for share buybacks or increases. The ongoing pressure from domestic medical supply procurement and overseas tariff risks could further impact the company's profitability [9]. - The company faces challenges from pricing pressures and increased competition due to healthcare reforms and policies that may lead to price reductions in medical devices, which could affect future profitability [9].

Group 1 - The company, Huangshan Gujie (301581), is committed to enhancing its profitability by developing new products and expanding application scenarios while maintaining its existing main business products [1] - The company is closely monitoring new trends, new tracks, and new demands in the industry to identify potential growth opportunities [1] - The company aims to deliver good performance to reward its investors [1]

Core Viewpoint - Feirongda (300602.SZ) has not yet engaged in the diamond copper substrate business but is actively monitoring developments in related technology fields and is committed to new product development and technology reserves to enhance its overall competitive advantage [1] Group 1 - The company is currently not involved in the diamond copper substrate business [1] - The company will actively pay attention to the development dynamics in related technology fields [1] - The company is focused on new product development and technology reserves to improve its competitive edge [1]

Investment Rating - The investment rating for the company is "Outperform" (Maintain) [1] Core Views - The company is experiencing short-term operational pressure due to increased competition and weak demand during the holiday season. However, new channels and products are expected to support improvement in the long term [5][6] - Revenue and net profit for the first three quarters of 2025 decreased by 5.4% and 73.2% year-on-year, respectively. The company has adjusted its profit forecasts for 2025-2027, predicting net profits of 3.4 billion, 5.8 billion, and 6.4 billion yuan, respectively [4][6] - The company is actively developing new products and expanding into new channels, which is anticipated to gradually improve overall operations [7] Financial Performance Summary - For the first three quarters of 2025, the company's revenue was 4.5 billion yuan, and net profit was 168 million yuan, reflecting a year-on-year decline of 5.4% and 73.2%, respectively [4] - The gross margin and net margin for Q3 2025 were 24.5% and 4.5%, down 8.6 percentage points and 11.0 percentage points year-on-year, primarily due to rising raw material costs and increased sales expenses [6] - The company has launched new products such as the Mountain Wild series of sunflower seeds and ice cream, which are expected to contribute to revenue growth [7] Financial Forecasts - The company's revenue is projected to be 6.89 billion yuan in 2025, with a year-on-year decline of 3.4%. The net profit is expected to be 338 million yuan, reflecting a significant decrease of 60.2% [8] - The gross margin is forecasted to be 21.3% in 2025, with a gradual recovery expected in subsequent years [8] - The price-to-earnings ratio (P/E) for 2025 is estimated at 32.9 times, decreasing to 19.1 times in 2026 and 17.4 times in 2027 [8]